Paper42579188
Stem-like characteristics across sequentially temozolomide-adapted glioblastoma cell populations with increasing levels of acquired resistance.
Sari DH and 3 others. Mol Biol Rep, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Stem-like characteristics across sequentially temozolomide-adapted glioblastoma cell populations with increasing levels of acquired resistance. Papers, record 42579188. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42579188
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Stem-like characteristics across sequentially temozolomide-adapted glioblastoma cell populations with increasing levels of acquired resistance.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Temozolomide | Major topic |
| Glioblastoma | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Neoplastic Stem Cells | Major topic |
| Humans | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Vimentin | |
| Antineoplastic Agents, Alkylating | |
| SOXB1 Transcription Factors | |
| Gene Expression Regulation, Neoplastic | |
| Octamer Transcription Factor-3 | |
| Brain Neoplasms | |
| AC133 Antigen | |
| Matrix Metalloproteinase 2 |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| PUTI Q2 Research Grant (Number: NKB-651/UN2.RST/HKP.05.00/2024) | Direktorat Riset and Pengembangan, Universitas Indonesia | PubMed | ||
| PUTI Q2 Research Grant (Number: NKB-651/UN2.RST/HKP.05.00/2024) | Direktorat Riset and Pengembangan, Universitas Indonesia | PubMed | ||
| PUTI Q2 Research Grant (Number: NKB-651/UN2.RST/HKP.05.00/2024) | Direktorat Riset and Pengembangan, Universitas Indonesia | PubMed | ||
| PUTI Q2 Research Grant (Number: NKB-651/UN2.RST/HKP.05.00/2024) | Direktorat Riset and Pengembangan, Universitas Indonesia | PubMed |
Source PubMed
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26314899 | Dissecting the role of distinct OCT4-SOX2 heterodimer configurations in pluripotency. | Sci Rep | 2015 | https://conductscience.org/library/papers/26314899 | PubMed |
| 2 | 27109183 | Nogo-A inhibits the migration and invasion of human malignant glioma U87MG cells. | Oncol Rep | 2016 | https://conductscience.org/library/papers/27109183 | PubMed |
| 3 | 34337348 | Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. | Cancer Drug Resist | 2021 | https://conductscience.org/library/papers/34337348 | PubMed |
| 4 | 38329598 | Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. | Cancer Metastasis Rev | 2024 | https://conductscience.org/library/papers/38329598 | PubMed |
| 5 | 33614649 | Temozolomide Treatment Induces HMGB1 to Promote the Formation of Glioma Stem Cells via the TLR2/NEAT1/Wnt Pathway in Glioblastoma. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/33614649 | PubMed |
| 6 | 40461793 | Acquired resistance in cancer: towards targeted therapeutic strategies. | Nat Rev Cancer | 2025 | https://conductscience.org/library/papers/40461793 | PubMed |
| 7 | 40346362 | Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics. | Nat Genet | 2025 | https://conductscience.org/library/papers/40346362 | PubMed |
| 8 | 30999923 | OCT4 and PAX6 determine the dual function of SOX2 in human ESCs as a key pluripotent or neural factor. | Stem Cell Res Ther | 2019 | https://conductscience.org/library/papers/30999923 | PubMed |
| 9 | 31907355 | Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. | Cell Death Dis | 2020 | https://conductscience.org/library/papers/31907355 | PubMed |
| 10 | 34427324 | Brain and other central nervous system tumor statistics, 2021. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/34427324 | PubMed |
| 11 | 35274101 | Expression of pluripotency-related genes in human glioblastoma. | Neurooncol Adv | 2022 | https://conductscience.org/library/papers/35274101 | PubMed |
| 12 | 34932099 | Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma. | Neuro Oncol | 2022 | https://conductscience.org/library/papers/34932099 | PubMed |
| 13 | 38158149 | Mitochondrial Mechanisms in Temozolomide Resistance: Unraveling the Complex Interplay and Therapeutic Strategies in Glioblastoma. | Mitochondrion | 2024 | https://conductscience.org/library/papers/38158149 | PubMed |
| 14 | 39589998 | Recapitulating Glioma Stem Cell Niches Using 3D Spheroid Models for Glioblastoma Research. | Biosensors (Basel) | 2024 | https://conductscience.org/library/papers/39589998 | PubMed |
| 15 | 35710946 | Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity. | Nat Rev Cancer | 2022 | https://conductscience.org/library/papers/35710946 | PubMed |
| 16 | 37444568 | Emerging Role of Glioma Stem Cells in Mechanisms of Therapy Resistance. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37444568 | PubMed |
| 17 | 41102523 | CRISPR screen reveals SOX2 as a critical regulator of CD133 and cellular stress response in glioblastoma. | Sci Rep | 2025 | https://conductscience.org/library/papers/41102523 | PubMed |
| 18 | 41013839 | Cancer cell plasticity and therapeutic resistance: mechanisms, crosstalk, and translational perspectives. | Hereditas | 2025 | https://conductscience.org/library/papers/41013839 | PubMed |
| 19 | 40468460 | Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights. | Acta Neuropathol Commun | 2025 | https://conductscience.org/library/papers/40468460 | PubMed |
| 20 | 40253386 | Temozolomide promotes glioblastoma stemness expression through senescence-associated reprogramming via HIF1α/HIF2α regulation. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/40253386 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MMP2 | 4313 | PubTator's text mining | https://conductscience.org/library/genes/4313 | NCBI Gene |
| POU5F1 | 5460 | PubTator's text mining | https://conductscience.org/library/genes/5460 | NCBI Gene |
| PROM1 | 8842 | PubTator's text mining | https://conductscience.org/library/genes/8842 | NCBI Gene |
| SOX2 | 6657 | PubTator's text mining | https://conductscience.org/library/genes/6657 | NCBI Gene |
| VIM | 7431 | PubTator's text mining | https://conductscience.org/library/genes/7431 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42579188
GET https://conductscience.org/api/papers/v1/42579188/references?page=2